Journal
ANTIVIRAL RESEARCH
Volume 172, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2019.104607
Keywords
Simeprevir; ZIKV; EV-A71; HSV-1; IFN-beta; ISG15
Categories
Funding
- National Key Basic Research Programs of China [2015CB554302, 2016YFE0133500, 2018YFA0507300]
- Natural Science Foundation of China [81830049, 81761128012, 31570895, 31600146]
- Shanghai Sailing Program [16YF1412400]
- Shanghai Natural Science Foundation [16ZR1439900]
- TOTAL foundation
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDB29030303]
- International Partnership Program of the Chinese Academy of Sciences [153831KYSB20190008]
Ask authors/readers for more resources
Simeprevir was developed as a small molecular drug targeting the NS3/4A protease of hepatitis C virus (HCV). Unexpectedly, our current work discovered that Simeprevir effectively promoted the transcription of IFN-beta and ISG15, inhibited the infection of host cells by multiple viruses including Zika virus (ZIKV), Enterovirus A71 (EV-A71), as well as herpes simplex virus type 1 (HSV-1). However, the inhibitory effects of Simeprevir on ZIKV, EV-A71 and HSV-1 were independent from IFN-beta and ISG15. This study thus demonstrates that the application of Simeprevir can be extended to other viruses besides HCV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
